The North America Gastric Cancer Market would witness market growth of 17.1% CAGR during the forecast period (2023-2029).
Interstitial cells of Cajal, are extremely early kinds of cells in the stomach wall, are where these rare malignancies begin. Some GISTs are far more likely than others to spread to different sections of the body or to grow into new locations. GISTs can begin anywhere throughout the digestive tract, although most begin in the stomach. Cells in the stomach (or other regions of the digestive system) that operate in some ways, like nerve cells, and in other ways, like hormone-producing (endocrine) cells, are where neuroendocrine tumors (NETs) originate. The majority of NETs grow gradually and never spread to other organs; however, some do.
Scientists have identified several risk factors that increase a person's likelihood of developing gastric cancer. For example, men and women are more likely to develop gastric cancer. Although gastric cancer can develop in younger people, the risk increases with age.
In the US, 85.6 percent of adults aged 18 and older reported having consumed alcohol at some point in their lives, 69.5 percent said they had done so in the year prior, and 54.9 percent said they had done so in the previous month (59.1 percent of men and 51.0 percent of women in this age group reported having done so). In 2019, 6.3% of adults (18 and older) reported significant alcohol consumption in the same period, 25.8% of adults (18 and older) reported binge drinking in the previous month (29.7% of men in this age group and 22.2 percent of women in this age group). The market for gastric cancer is anticipated to grow in the region as a result.
The US market dominated the North America Gastric Cancer Market by Country in 2022 and would continue to be a dominant market till 2029; thereby, achieving a market value of $1,377.4 million by 2029. The Canada market is poised to grow at a CAGR of 19.8% during (2023 - 2029). Additionally, The Mexico market would witness a CAGR of 18.7% during (2023 - 2029).
Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, and Radiation Therapy & Surgery. Based on Disease Type, the market is segmented into Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor, Lymphoma and Others. Based on Distribution Channel, the market is segmented into Specialty & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Gastric Cancer Market is Projected to reach USD 6.9 Billion by 2029, at a CAGR of 17.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Pfizer, Inc., Viatris, Inc. (Mylan N.V.), F. Hoffmann-La Roche Ltd., Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.).
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration
By Treatment Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy & Surgery
By Disease Type
- Adenocarcinoma
- Carcinoid Tumor
- Gastrointestinal Stromal Tumor
- Lymphoma
- Others
By Distribution Channel
- Specialty & Retail Pharmacies
- Hospital Pharmacies
- Others
By Drug Class
- PD-1/PD-L1 Inhibitors
- HER2 Antagonists
- VEGFR2 Antagonists
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Pfizer, Inc.
- Viatris, Inc. (Mylan N.V.)
- F. Hoffmann-La Roche Ltd.
- Eli Lilly And Company
- Merck & Co., Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bristol Myers Squibb Company
- Celltrion Healthcare Co., Ltd.
- Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Gastric Cancer Market, by Route of Administration
1.4.2 North America Gastric Cancer Market, by Treatment Type
1.4.3 North America Gastric Cancer Market, by Disease Type
1.4.4 North America Gastric Cancer Market, by Distribution Channel
1.4.5 North America Gastric Cancer Market, by Drug Class
1.4.6 North America Gastric Cancer Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals & Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. North America Gastric Cancer Market by Route of Administration
4.1 North America Injectable Market by Country
4.2 North America Oral Market by Country
Chapter 5. North America Gastric Cancer Market by Treatment Type
5.1 North America Chemotherapy Market by Country
5.2 North America Targeted Therapy Market by Country
5.3 North America Immunotherapy Market by Country
5.4 North America Radiation Therapy & Surgery Market by Country
Chapter 6. North America Gastric Cancer Market by Disease Type
6.1 North America Adenocarcinoma Market by Country
6.2 North America Carcinoid Tumor Market by Country
6.3 North America Gastrointestinal Stromal Tumor Market by Country
6.4 North America Lymphoma Market by Country
6.5 North America Others Market by Country
Chapter 7. North America Gastric Cancer Market by Distribution Channel
7.1 North America Specialty & Retail Pharmacies Market by Country
7.2 North America Hospital Pharmacies Market by Country
7.3 North America Others Market by Country
Chapter 8. North America Gastric Cancer Market by Drug Class
8.1 North America PD-1/PD-L1 Inhibitors Market by Country
8.2 North America HER2 Antagonists Market by Country
8.3 North America VEGFR2 Antagonists Market by Country
8.4 North America Others Market by Country
Chapter 9. North America Gastric Cancer Market by Country
9.1 US Gastric Cancer Market
9.1.1 US Gastric Cancer Market by Route of Administration
9.1.2 US Gastric Cancer Market by Treatment Type
9.1.3 US Gastric Cancer Market by Disease Type
9.1.4 US Gastric Cancer Market by Distribution Channel
9.1.5 US Gastric Cancer Market by Drug Class
9.2 Canada Gastric Cancer Market
9.2.1 Canada Gastric Cancer Market by Route of Administration
9.2.2 Canada Gastric Cancer Market by Treatment Type
9.2.3 Canada Gastric Cancer Market by Disease Type
9.2.4 Canada Gastric Cancer Market by Distribution Channel
9.2.5 Canada Gastric Cancer Market by Drug Class
9.3 Mexico Gastric Cancer Market
9.3.1 Mexico Gastric Cancer Market by Route of Administration
9.3.2 Mexico Gastric Cancer Market by Treatment Type
9.3.3 Mexico Gastric Cancer Market by Disease Type
9.3.4 Mexico Gastric Cancer Market by Distribution Channel
9.3.5 Mexico Gastric Cancer Market by Drug Class
9.4 Rest of North America Gastric Cancer Market
9.4.1 Rest of North America Gastric Cancer Market by Route of Administration
9.4.2 Rest of North America Gastric Cancer Market by Treatment Type
9.4.3 Rest of North America Gastric Cancer Market by Disease Type
9.4.4 Rest of North America Gastric Cancer Market by Distribution Channel
9.4.5 Rest of North America Gastric Cancer Market by Drug Class
Chapter 10. Company Profiles
10.1 Novartis AG
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.2 Pfizer, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional & Segmental Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Partnerships, Collaborations, and Agreements:
10.3 Viatris, Inc. (Mylan N.V.)
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Product Launches and Product Expansions:
10.3.5.2 Approvals & Trials:
10.4 F. Hoffmann-La Roche Ltd.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Partnerships, Collaborations, and Agreements:
10.4.5.2 Product Launches and Product Expansions:
10.5 Eli Lilly And Company
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Regional Analysis
10.5.4 Research & Development Expenses
10.5.5 Recent strategies and developments:
10.5.5.1 Approvals & Trials:
10.5.5.2 Partnerships, Collaborations, and Agreements:
10.6 Merck & Co., Inc.
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 Teva Pharmaceutical Industries Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.7.5 Recent strategies and developments:
10.7.5.1 Product Launches and Product Expansions:
10.7.5.2 Approvals & Trials:
10.7.5.3 Partnerships, Collaborations, and Agreements:
10.8 Bristol Myers Squibb Company
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Approvals & Trials:
10.9 Celltrion Healthcare Co., Ltd.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Recent strategies and developments:
10.9.3.1 Partnerships, Collaborations, and Agreements:
10.10. Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expenses
10.10.5 Recent strategies and developments:
10.10.5.1 Approvals & Trials:
10.10.5.2 Product Launches and Product Expansions:
TABLE 1 North America Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 2 North America Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Gastric Cancer Market
TABLE 4 Product Launches And Product Expansions– Gastric Cancer Market
TABLE 5 Approvals & Trials – Gastric Cancer Market
TABLE 6 North America Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 7 North America Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 8 North America Injectable Market by Country, 2019 - 2022, USD Million
TABLE 9 North America Injectable Market by Country, 2023 - 2029, USD Million
TABLE 10 North America Oral Market by Country, 2019 - 2022, USD Million
TABLE 11 North America Oral Market by Country, 2023 - 2029, USD Million
TABLE 12 North America Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 13 North America Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 14 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 15 North America Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 16 North America Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 17 North America Targeted Therapy Market by Country, 2023 - 2029, USD Million
TABLE 18 North America Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 19 North America Immunotherapy Market by Country, 2023 - 2029, USD Million
TABLE 20 North America Radiation Therapy & Surgery Market by Country, 2019 - 2022, USD Million
TABLE 21 North America Radiation Therapy & Surgery Market by Country, 2023 - 2029, USD Million
TABLE 22 North America Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 23 North America Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 24 North America Adenocarcinoma Market by Country, 2019 - 2022, USD Million
TABLE 25 North America Adenocarcinoma Market by Country, 2023 - 2029, USD Million
TABLE 26 North America Carcinoid Tumor Market by Country, 2019 - 2022, USD Million
TABLE 27 North America Carcinoid Tumor Market by Country, 2023 - 2029, USD Million
TABLE 28 North America Gastrointestinal Stromal Tumor Market by Country, 2019 - 2022, USD Million
TABLE 29 North America Gastrointestinal Stromal Tumor Market by Country, 2023 - 2029, USD Million
TABLE 30 North America Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 31 North America Lymphoma Market by Country, 2023 - 2029, USD Million
TABLE 32 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 33 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 34 North America Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 35 North America Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 36 North America Specialty & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 37 North America Specialty & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 38 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 39 North America Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 40 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 41 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 42 North America Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 43 North America Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 44 North America PD-1/PD-L1 Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 45 North America PD-1/PD-L1 Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 46 North America HER2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 47 North America HER2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 48 North America VEGFR2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 49 North America VEGFR2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 50 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 51 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 52 North America Gastric Cancer Market by Country, 2019 - 2022, USD Million
TABLE 53 North America Gastric Cancer Market by Country, 2023 - 2029, USD Million
TABLE 54 US Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 55 US Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 56 US Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 57 US Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 58 US Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 59 US Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 60 US Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 61 US Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 62 US Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 63 US Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 64 US Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 65 US Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 66 Canada Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 67 Canada Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 68 Canada Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 69 Canada Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 70 Canada Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 71 Canada Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 72 Canada Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 73 Canada Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 74 Canada Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 75 Canada Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 76 Canada Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 77 Canada Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 78 Mexico Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 79 Mexico Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 80 Mexico Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 81 Mexico Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 82 Mexico Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 83 Mexico Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 84 Mexico Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 85 Mexico Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 86 Mexico Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 87 Mexico Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 88 Mexico Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 89 Mexico Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 90 Rest of North America Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 91 Rest of North America Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 92 Rest of North America Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 93 Rest of North America Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 94 Rest of North America Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 95 Rest of North America Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 96 Rest of North America Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 97 Rest of North America Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 98 Rest of North America Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 99 Rest of North America Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 100 Rest of North America Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 101 Rest of North America Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 102 Key Information – Novartis AG
TABLE 103 Key Information – Pfizer, Inc.
TABLE 104 key information – Viatris, Inc.
TABLE 105 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 106 Key Information – Eli Lilly And Company
TABLE 107 KEY INFORMATION - Merck & Co., Inc.
TABLE 108 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 109 Key Information – Bristol Myers Squibb Company
TABLE 110 Key Information – Celltrion Healthcare Co., Ltd.
TABLE 111 Key Information – Samsung Biologics Co., Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Recent strategies and developments: Viatris, Inc.
FIG 5 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 6 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
FIG 7 Recent strategies and developments: Samsung Biologics Co., Ltd.